BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mima K, Nakagawa S, Sawayama H, Ishimoto T, Imai K, Iwatsuki M, Hashimoto D, Baba Y, Yamashita YI, Yoshida N, Chikamoto A, Baba H. The microbiome and hepatobiliary-pancreatic cancers.Cancer Lett. 2017;402:9-15. [PMID: 28527946 DOI: 10.1016/j.canlet.2017.05.001] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 11.4] [Reference Citation Analysis]
Number Citing Articles
1 Takáčová M, Bomba A, Tóthová C, Micháľová A, Turňa H. Any Future for Faecal Microbiota Transplantation as a Novel Strategy for Gut Microbiota Modulation in Human and Veterinary Medicine? Life 2022;12:723. [DOI: 10.3390/life12050723] [Reference Citation Analysis]
2 Seesaha PK, Wang KX, Wang GQ, Cui TY, Zhao FJ, Pan LL, Li XC, Shu YQ, Chen XF. Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer. Onco Targets Ther 2021;14:1873-82. [PMID: 33737812 DOI: 10.2147/OTT.S269671] [Reference Citation Analysis]
3 Choi IJ. [Helicobacter pylori Eradication Therapy and Gastric Cancer Prevention]. Korean J Gastroenterol 2018;72:245-51. [PMID: 30642140 DOI: 10.4166/kjg.2018.72.5.245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
4 Lee Y, Kamada N, Moon JJ. Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome. Adv Drug Deliv Rev 2021;179:114021. [PMID: 34710529 DOI: 10.1016/j.addr.2021.114021] [Reference Citation Analysis]
5 Feng X, Han L, Ma S, Zhao L, Wang L, Zhang K, Yin P, Guo L, Jing W, Li Q. Microbes in Tumoral In Situ Tissues and in Tumorigenesis. Front Cell Infect Microbiol 2020;10:572570. [PMID: 33330121 DOI: 10.3389/fcimb.2020.572570] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Huang PY, Yang YC, Wang CI, Hsiao PW, Chiang HI, Chen TW. Increase in Akkermansiaceae in Gut Microbiota of Prostate Cancer-Bearing Mice. Int J Mol Sci 2021;22:9626. [PMID: 34502535 DOI: 10.3390/ijms22179626] [Reference Citation Analysis]
7 Herrera S, Martínez-Sanz J, Serrano-Villar S. HIV, Cancer, and the Microbiota: Common Pathways Influencing Different Diseases. Front Immunol 2019;10:1466. [PMID: 31316514 DOI: 10.3389/fimmu.2019.01466] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
8 Parker KD, Maurya AK, Ibrahim H, Rao S, Hove PR, Kumar D, Kant R, Raina B, Agarwal R, Kuhn KA, Raina K, Ryan EP. Dietary Rice Bran-Modified Human Gut Microbial Consortia Confers Protection against Colon Carcinogenesis Following Fecal Transfaunation. Biomedicines 2021;9:144. [PMID: 33546192 DOI: 10.3390/biomedicines9020144] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Herreros-Pomares A, Llorens C, Soriano B, Zhang F, Gallach S, Bagan L, Murillo J, Jantus-Lewintre E, Bagan J. Oral microbiome in Proliferative Verrucous Leukoplakia exhibits loss of diversity and enrichment of pathogens. Oral Oncol 2021;120:105404. [PMID: 34225130 DOI: 10.1016/j.oraloncology.2021.105404] [Reference Citation Analysis]
10 Mao Q, Jiang F, Yin R, Wang J, Xia W, Dong G, Ma W, Yang Y, Xu L, Hu J. Interplay between the lung microbiome and lung cancer. Cancer Lett 2018;415:40-8. [PMID: 29197615 DOI: 10.1016/j.canlet.2017.11.036] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 13.0] [Reference Citation Analysis]
11 Dangtakot R, Intuyod K, Ahooja A, Wongwiwatchai J, Hanpanich P, Lulitanond A, Chamgramol Y, Pinlaor S, Pinlaor P. Profiling of Bile Microbiome Identifies District Microbial Population between Choledocholithiasis and Cholangiocarcinoma Patients. Asian Pac J Cancer Prev 2021;22:233-40. [PMID: 33507704 DOI: 10.31557/APJCP.2021.22.1.233] [Reference Citation Analysis]
12 Mikó E, Kovács T, Sebő É, Tóth J, Csonka T, Ujlaki G, Sipos A, Szabó J, Méhes G, Bai P. Microbiome-Microbial Metabolome-Cancer Cell Interactions in Breast Cancer-Familiar, but Unexplored. Cells 2019;8:E293. [PMID: 30934972 DOI: 10.3390/cells8040293] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 15.3] [Reference Citation Analysis]
13 Petrelli F, Ghidini M, Ghidini A, Perego G, Cabiddu M, Khakoo S, Oggionni E, Abeni C, Hahne JC, Tomasello G, Zaniboni A. Use of Antibiotics and Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies. Cancers (Basel) 2019;11:E1174. [PMID: 31416208 DOI: 10.3390/cancers11081174] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
14 Liang Y, Ming Q, Liang J, Zhang Y, Zhang H, Shen T. Gut microbiota dysbiosis in polycystic ovary syndrome: association with obesity - a preliminary report. Can J Physiol Pharmacol. 2020;98:803-809. [PMID: 32150694 DOI: 10.1139/cjpp-2019-0413] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
15 Aindelis G, Chlichlia K. Modulation of Anti-Tumour Immune Responses by Probiotic Bacteria. Vaccines (Basel) 2020;8:E329. [PMID: 32575876 DOI: 10.3390/vaccines8020329] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
16 Dikilitas M. Why Adjuvant and Neoadjuvant Therapy Failed in HCC. Can the New Immunotherapy Be Expected to Be Better? J Gastrointest Cancer 2020;51:1193-6. [PMID: 32869146 DOI: 10.1007/s12029-020-00497-7] [Reference Citation Analysis]
17 Fulgenzi CAM, Talbot T, Murray SM, Silletta M, Vincenzi B, Cortellini A, Pinato DJ. Immunotherapy in Hepatocellular Carcinoma. Curr Treat Options Oncol 2021;22:87. [PMID: 34424422 DOI: 10.1007/s11864-021-00886-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Pagliari D, Saviano A, Newton EE, Serricchio ML, Dal Lago AA, Gasbarrini A, Cianci R. Gut Microbiota-Immune System Crosstalk and Pancreatic Disorders. Mediators Inflamm 2018;2018:7946431. [PMID: 29563853 DOI: 10.1155/2018/7946431] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
19 Gaianigo N, Melisi D, Carbone C. EMT and Treatment Resistance in Pancreatic Cancer. Cancers (Basel). 2017;9:pii: E122. [PMID: 28895920 DOI: 10.3390/cancers9090122] [Cited by in Crossref: 57] [Cited by in F6Publishing: 66] [Article Influence: 11.4] [Reference Citation Analysis]
20 Dong J, Gao HL, Wang WQ, Yu XJ, Liu L. Bidirectional and dynamic interaction between the microbiota and therapeutic resistance in pancreatic cancer. Biochim Biophys Acta Rev Cancer 2021;1875:188484. [PMID: 33246025 DOI: 10.1016/j.bbcan.2020.188484] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Hua H, Zhang H, Kong Q, Wang J, Jiang Y. Complex roles of the old drug aspirin in cancer chemoprevention and therapy. Med Res Rev 2019;39:114-45. [PMID: 29855050 DOI: 10.1002/med.21514] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 10.3] [Reference Citation Analysis]
22 Won SM, Park E, Jeong JJ, Ganesan R, Gupta H, Gebru YA, Sharma S, Kim DJ, Suk KT. The Gut Microbiota-Derived Immune Response in Chronic Liver Disease. Int J Mol Sci 2021;22:8309. [PMID: 34361075 DOI: 10.3390/ijms22158309] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Ma Y, Qiu M, Wang S, Meng S, Yang F, Jiang G. Distinct tumor bacterial microbiome in lung adenocarcinomas manifested as radiological subsolid nodules. Transl Oncol 2021;14:101050. [PMID: 33765542 DOI: 10.1016/j.tranon.2021.101050] [Reference Citation Analysis]
24 Jiang H, Li J, Zhang B, Huang R, Zhang J, Chen Z, Shang X, Li X, Nie X. Intestinal Flora Disruption and Novel Biomarkers Associated With Nasopharyngeal Carcinoma. Front Oncol 2019;9:1346. [PMID: 31867274 DOI: 10.3389/fonc.2019.01346] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. Publisher Correction: The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 2018;15:785. [PMID: 29785003 DOI: 10.1038/s41575-018-0031-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
26 Garajová I, Balsano R, Wang H, Leonardi F, Giovannetti E, Deng D, Peters GJ. The role of the microbiome in drug resistance in gastrointestinal cancers. Expert Rev Anticancer Ther 2021;21:165-76. [PMID: 33115280 DOI: 10.1080/14737140.2021.1844007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
27 Kang YB, Cai Y. Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer. World J Gastroenterol 2021;27:5362-75. [PMID: 34539138 DOI: 10.3748/wjg.v27.i32.5362] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
28 Armstrong H, Bording-Jorgensen M, Dijk S, Wine E. The Complex Interplay between Chronic Inflammation, the Microbiome, and Cancer: Understanding Disease Progression and What We Can Do to Prevent It. Cancers (Basel) 2018;10:E83. [PMID: 29558443 DOI: 10.3390/cancers10030083] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
29 Bagheri Z, Moeinzadeh L, Razmkhah M. Roles of Microbiota in Cancer: From Tumor Development to Treatment. J Oncol 2022;2022:3845104. [PMID: 35342407 DOI: 10.1155/2022/3845104] [Reference Citation Analysis]
30 Ando K, Hu Q, Kasagi Y, Oki E, Mori M. Recent developments in cancer research: Expectations for a new remedy. Ann Gastroenterol Surg 2021;5:419-26. [PMID: 34337290 DOI: 10.1002/ags3.12440] [Reference Citation Analysis]
31 Martins Lopes MS, Machado LM, Ismael Amaral Silva PA, Tome Uchiyama AA, Yen CT, Ricardo ED, Mutao TS, Pimenta JR, Shimba DS, Hanriot RM, Peixoto RD. Antibiotics, cancer risk and oncologic treatment efficacy: a practical review of the literature. Ecancermedicalscience 2020;14:1106. [PMID: 33144874 DOI: 10.3332/ecancer.2020.1106] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Pothuraju R, Rachagani S, Junker WM, Chaudhary S, Saraswathi V, Kaur S, Batra SK. Pancreatic cancer associated with obesity and diabetes: an alternative approach for its targeting. J Exp Clin Cancer Res. 2018;37:319. [PMID: 30567565 DOI: 10.1186/s13046-018-0963-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
33 Nascimento FSD, Suzuki MO, Taba JV, de Mattos VC, Pipek LZ, D'Albuquerque EMC, Iuamoto L, Meyer A, Andraus W, Pinho JRR, de Moura EGH, Setubal JC, Carneiro-D'Albuquerque LA. Analysis of biliary MICRObiota in hepatoBILIOpancreatic diseases compared to healthy people [MICROBILIO]: Study protocol. PLoS One 2020;15:e0242553. [PMID: 33211762 DOI: 10.1371/journal.pone.0242553] [Reference Citation Analysis]
34 Druzhinin VG, Matskova LV, Fucic A. Induction and modulation of genotoxicity by the bacteriome in mammals. Mutat Res Rev Mutat Res 2018;776:70-7. [PMID: 29807578 DOI: 10.1016/j.mrrev.2018.04.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
35 Flynn MJ, Sayed AA, Sharma R, Siddique A, Pinato DJ. Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. Hepatology 2019;69:2258-70. [DOI: 10.1002/hep.30337] [Cited by in Crossref: 28] [Cited by in F6Publishing: 35] [Article Influence: 9.3] [Reference Citation Analysis]
36 Mendez R, Kesh K, Arora N, Di Martino L, McAllister F, Merchant N, Banerjee S, Banerjee S. Microbial dysbiosis and polyamine metabolism as predictive markers for early detection of pancreatic cancer. Carcinogenesis 2020;41:561-70. [PMID: 31369062 DOI: 10.1093/carcin/bgz116] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
37 Cammann S, Karabulut S, DeTemple DE, Oldhafer F, Kulik U, Schroeter A, Vondran FWR, Klempnauer J, Kleine M, Timrott K, Beetz O. Antibiotic-Resistant Bacteria Colonizing the Bile Duct Are Associated with Increased Morbidity and Mortality after Resection of Extrahepatic Cholangiocarcinoma. Surg Infect (Larchmt) 2022. [PMID: 35172114 DOI: 10.1089/sur.2021.117] [Reference Citation Analysis]
38 Ternák G, Berényi K, Sümegi A, Szenczi Á, Fodor B, Németh B, Kiss I. Antibiotic Consumption Patterns in European Countries May Be Associated with the Incidence of Major Carcinomas. Antibiotics (Basel) 2020;9:E643. [PMID: 32993020 DOI: 10.3390/antibiotics9100643] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
39 Labib PL, Goodchild G, Pereira SP. Molecular Pathogenesis of Cholangiocarcinoma. BMC Cancer. 2019;19:185. [PMID: 30819129 DOI: 10.1186/s12885-019-5391-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 59] [Article Influence: 16.7] [Reference Citation Analysis]
40 Yi M, Yu S, Qin S, Liu Q, Xu H, Zhao W, Chu Q, Wu K. Gut microbiome modulates efficacy of immune checkpoint inhibitors. J Hematol Oncol. 2018;11:47. [PMID: 29580257 DOI: 10.1186/s13045-018-0592-6] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 16.3] [Reference Citation Analysis]
41 Tao J, Li S, Gan RY, Zhao CN, Meng X, Li HB. Targeting gut microbiota with dietary components on cancer: Effects and potential mechanisms of action. Crit Rev Food Sci Nutr 2020;60:1025-37. [PMID: 30632784 DOI: 10.1080/10408398.2018.1555789] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
42 Deva AK. Response to "Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Why the Search for an Infectious Etiology May Be Irrelevant". Aesthet Surg J 2017;37:NP122-8. [PMID: 29025239 DOI: 10.1093/asj/sjx133] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
43 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15:397-411. [PMID: 29748586 DOI: 10.1038/s41575-018-0011-z] [Cited by in Crossref: 301] [Cited by in F6Publishing: 300] [Article Influence: 100.3] [Reference Citation Analysis]
44 Helmink BA, Khan MAW, Hermann A, Gopalakrishnan V, Wargo JA. The microbiome, cancer, and cancer therapy. Nat Med 2019;25:377-88. [DOI: 10.1038/s41591-019-0377-7] [Cited by in Crossref: 250] [Cited by in F6Publishing: 218] [Article Influence: 83.3] [Reference Citation Analysis]
45 Chen D, Wu J, Jin D, Wang B, Cao H. Fecal microbiota transplantation in cancer management: Current status and perspectives. Int J Cancer. 2018;. [PMID: 30458058 DOI: 10.1002/ijc.32003] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 15.0] [Reference Citation Analysis]
46 Deva AK, Turner SD, Kadin ME, Magnusson MR, Prince HM, Miranda RN, Inghirami GG, Adams WP Jr. Etiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Current Directions in Research. Cancers (Basel) 2020;12:E3861. [PMID: 33371292 DOI: 10.3390/cancers12123861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
47 Park R, Umar S, Kasi A. Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-augmented Clinical Trials. Curr Colorectal Cancer Rep 2020;16:81-8. [PMID: 32607098 DOI: 10.1007/s11888-020-00456-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
48 Bourdeleau P, Larrey E, Allaire M, Charlotte F, Vaillant JC, Lebray P. "De novo" cholangiocarcinoma 20 years after liver transplantation for primary sclerosing cholangitis: Lifelong screening needed! Clin Res Hepatol Gastroenterol 2021;46:101827. [PMID: 34740844 DOI: 10.1016/j.clinre.2021.101827] [Reference Citation Analysis]
49 Ren Y, Su H, She Y, Dai C, Xie D, Narrandes S, Huang S, Chen C, Xu W. Whole genome sequencing revealed microbiome in lung adenocarcinomas presented as ground-glass nodules. Transl Lung Cancer Res 2019;8:235-46. [PMID: 31367537 DOI: 10.21037/tlcr.2019.06.11] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
50 Kiss B, Mikó E, Sebő É, Toth J, Ujlaki G, Szabó J, Uray K, Bai P, Árkosy P. Oncobiosis and Microbial Metabolite Signaling in Pancreatic Adenocarcinoma. Cancers (Basel) 2020;12:E1068. [PMID: 32344895 DOI: 10.3390/cancers12051068] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
51 Cianci R, Franza L, Schinzari G, Rossi E, Ianiro G, Tortora G, Gasbarrini A, Gambassi G, Cammarota G. The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer. Int J Mol Sci 2019;20:E501. [PMID: 30682772 DOI: 10.3390/ijms20030501] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
52 Wang Q, Ding H, Dong G, Xu L, Jiang F, Mao Q. Bi-direction effects between microbiome and MiRNAs in carcinogenesis. J Cancer Res Clin Oncol 2021;147:1299-305. [PMID: 33765216 DOI: 10.1007/s00432-021-03567-w] [Reference Citation Analysis]
53 Brocco D, Florio R, De Lellis L, Veschi S, Grassadonia A, Tinari N, Cama A. The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective. Cancers (Basel) 2020;12:E1849. [PMID: 32659999 DOI: 10.3390/cancers12071849] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
54 Dai X, Wang S, Niu C, Ji B, Liu Y. Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma. Technol Cancer Res Treat 2020;19:153303382094748. [DOI: 10.1177/1533033820947486] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 El Bairi K, Jabi R, Trapani D, Boutallaka H, Ouled Amar Bencheikh B, Bouziane M, Amrani M, Afqir S, Maleb A. Can the microbiota predict response to systemic cancer therapy, surgical outcomes, and survival? The answer is in the gut. Expert Rev Clin Pharmacol 2020;13:403-21. [PMID: 32308061 DOI: 10.1080/17512433.2020.1758063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Hack SP, Verret W, Mulla S, Liu B, Wang Y, Macarulla T, Ren Z, El-Khoueiry AB, Zhu AX. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Ther Adv Med Oncol 2021;13:17588359211036544. [PMID: 34377158 DOI: 10.1177/17588359211036544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]